Variable capacity of 13 hepatitis B virus surface antigen assays for the detection of HBsAg mutants in blood samples

Journal of Clinical Virology

Volumn 53, Issue 4, 2012, Pages 338-345

  Servant Delmas, Annabelle ^a   Mercier Darty, Mélanie ^a   Ly, Thoai Duong ^b   Wind, Françoise ^c   Alloui, Chakib ^d   Sureau, Camille ^a   Laperche, Syria ^a  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b Laboratoire Biomnis   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d AVICENNE HOSPITAL   (France)

Author keywords

HBsAg variants detection; HBV; Immunoassays; Sensitivity

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; PROTEIN VARIANT;

ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; IMMUNOASSAY; LIMIT OF DETECTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SUBSTITUTION REACTION;

BLOOD DONORS; GENETIC VARIATION; GENOTYPE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOASSAY; LIMIT OF DETECTION; MUTATION; REAGENT KITS, DIAGNOSTIC; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY;

EID: 84858150106     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.01.003     Document Type: Article

References (31)

1. Carman W.F., Van Deursen F.J., Mimms L.T., Hardie D., Coppola R., Decker R., et al. The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa, and Sardinia. Hepatology 1997, 26(6):1658-1666.
2. Hsu H.Y., Chang M.H., Liaw S.H., Ni Y.H., Chen H.L. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 1999, 30(November (5)):1312-1317.
3. Hsu H.Y., Chang M.H., Ni Y.H., Chen H.L. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 2004, 53(October (10)):1499-1503.
4. Yamamoto K., Horikita M., Tsuda F., Itoh K., Akahane Y., Yotsumoto S., et al. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 1994, 68(4):2671-2676.
5. Seddigh-Tonekaboni S., Waters J.A., Jeffers S., Gehrke R., Ofenloch B., Horsch A., et al. Effect of variation in the common a determinant on the antigenicity of hepatitis B surface antigen. J Med Virol 2000, 60(2):113-121.
6. Ly T.D., Servant-Delmas A., Bagot S., Gonzalo S., Ferey M.P., Ebel A., et al. Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J Clin Microbiol 2006, 44(July (7)):2321-2326.
7. Jeantet D., Chemin I., Mandrand B., Tran A., Zoulim F., Merle P., et al. Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. J Med Virol 2004, 73(August (4)):508-515.
8. Moerman B., Moons V., Sommer H., Schmitt Y., Stetter M. Evaluation of sensitivity for wild type and mutant forms of hepatitis B surface antigen by four commercial HBsAg assays. Clin Lab 2004, 50(3-4):159-162.
9. Gerlich W. Breakthrough of hepatitis B virus escape mutants after vaccination and virus reactivation. J Clin Virol 2006, 36:S18-S22.
10. Louisirirotchanakul S., Khupulsup K., Akraekthalin S., Chan K.P., Saw S., Aw T.C., et al. Comparison of the technical and clinical performance of the Elecsys HBsAg II assay with the Architect, AxSym, and Advia Centaur HBsAg screening assays. J Med Virol 2010, 82(May (5)):755-762.
11. El Chaar M., Candotti D., Crowther R.A., Allain J.P. Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology 2010, 52(November (5)):1600-1610. [Research Support, Non-U.S. Govt.].
12. Kuhns M., McNamara A., Holzmayer V., Lou S., Busch M. Frequency of diagnostically significant hepatitis B surface antigen mutants. J Med Virol 2007, 79:S42-S46.
13. Servant-Delmas A., Mercier M., ElGhouzzi M-H., Girault A., Bouchardeau F., Pillonel J., et al. National survey of hepatitis B virus polymorphism in asymptomatic HBV blood donors from 1999 to 2007 in France. Transfusion 2010, 12:2607-2618.
14. Ali A., Pearce S., Coleman P. Factors affecting immunodetection of hepatitis B surface antigen recombinant mutants. J Med Virol 2007, 79(Suppl. 1):S47-S51.
15. Nick S., Scheiblauer H. Sensitivities of CE-marked HIV, HCV and HBsAg assays. J Med Virol 2007, 79:S59-S64.
16. European Union Commission decision of 3 February 2009 on common technical specifications for in vitro diagnostic medical devices 2002/364/EC. Off J Eur Commun 2009, L39/4-/49.
17. Avellon A., Echevarria J.M., Weber B., Weik M., Schobel U., Willems W.R., et al. European collaborative evaluation of the Enzygnost HBsAg 6.0 assay: performance on hepatitis B virus surface antigen variants. J Med Virol 2011, 83(January (1)):95-100.
18. Mühlbacher B., Weber B., Bürgisser P., Eiras A., Cabrera J., Louisirirotchanakul S., et al. Multicenter study of a new fully automated HBsAg screening assay with enhanced sensitivity for the detection of HBV mutants. Med Microbiol Immunol 2008, 197:55-64.
19. Echevarria J.M., Avellon A. Improved detection of natural hepatitis B virus surface antigen (HBsAg) mutants by a new version of the VITROS HBsAg assay. J Med Virol 2008, 80(April (4)):598-602. [Comparative Study. Evaluation Studies Research Support, Non-U.S. Govt.].
20. Weber B., Dengler T., Berger A., Doerr H.W., Rabenau H. Evaluation of two new automated assays for hepatitis B virus surface antigen (HBsAg) detection: IMMULITE HBsAg and IMMULITE 2000 HBsAg. J Clin Microbiol 2003, 41(January (1)):135-143.
21. Moucari R., Marcellin P. Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B. Liver Int 2011, 31(January (Suppl. 1)):122-128. [Review].
22. Chan H.L., Thompson A., Martinot-Peignoux M., Piratvisuth T., Cornberg M., Brunetto M.R., et al. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J Hepatol 2011, 55(November (5)):1121-1131.
23. Jaroszewicz J., Calle Serrano B., Wursthorn K., Deterding K., Schlue J., Raupach R., et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010, 52(April (4)):514-522.
24. Jongerius J.M., Wester M., Cuypers H.T., van Oostendorp W.R., Lelie P.N., van der Poel C.L., et al. New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. Transfusion 1998, 38(1):56-59.
25. Levicnik-Stezinar S. Hepatitis B surface antigen escape mutant in a first time blood donor potentially missed by a routine screening assay. Clin Lab 2004, 50(1-2):49-51.
26. Zeiler T., Karger R., Slonka J., Ketschmer V., Radsak K. Introduction of anti-HBc testing of blood donors in Germany. Transfus Med 2006, 16(6):441-443.
27. Kamili S., Sozzi V., Thompson G., Campbell K., Walker C.M., Locarnini S., et al. Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology 2009, 49(May (5)):1483-1491. [Evaluation studies].
28. Park N.H., Chung Y.H., Lee H.S. Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. Intervirology 2010, 53(1):20-28.
29. Chang M.H. Breakthrough HBV infection in vaccinated children in Taiwan: surveillance for HBV mutants. Antivir Ther 2010, 15(3 (Pt B)):463-469. [Research Support, Non-U.S. Govt., Review].
30. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 2002, 25(August (2)):97-106.
31. Lou S.C., Pearce S.K., Lukaszewska T.X., Taylor R.E., Williams G.T., Leary T.P. An improved Abbott ARCHITECT assay for the detection of hepatitis B virus surface antigen (HBsAg). J Clin Virol 2011, 51(1):59-63.